NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) PCT Platform Featured in ProCan Scientific Team’s Sample Preparation Protocol
Pressure BioSciences (OTCQB: PBIO) today announced that a Centre for the Proteome of Human Cancer (“ProCan”) scientific team has published a recommended sample preparation protocol built around PBIO’s Barocycler instrument system, which is designed to improve diagnosis and treatment of cancers through optimizing the identification and use of novel biomarkers. Per the update, ProCan scientists have named the new protocol Accelerated Barocycler Lysis and Extraction (“ABLE”), which is based on PBIO’s proprietary pressure cycling technology (“PCT”) platform for the rapid breakup of tissue samples and release of molecules for analysis. “We are pleased that ProCan has developed an advanced sample processing system, featuring the use of our Barocycler instrument system,” PBIO Senior VP and Chief Commercial Officer Dr. Bradford Young stated in the news release. “The ABLE method will enable scientists worldwide to benefit from the advantages of our PCT platform technology for cancer profiling and drug development, as reported by ProCan scientists and their colleagues. We believe the ABLE method has the potential to help transform the way cancer is diagnosed and treated for improved patient outcomes.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO) today announced that a Centre for the Proteome of Human Cancer (“ProCan”) scientific team has published a recommended sample preparation protocol built around PBIO’s Barocycler instrument system, which is designed to improve diagnosis and treatment of cancers through optimizing the identification and use of novel biomarkers. Per the update, ProCan scientists have named the new protocol Accelerated Barocycler Lysis and Extraction (“ABLE”), which is based on PBIO’s proprietary pressure cycling technology (“PCT”) platform for the rapid breakup of tissue samples and release of molecules for analysis. “We are pleased that ProCan has developed an advanced sample processing system, featuring the use of our Barocycler instrument system,” PBIO Senior VP and Chief Commercial Officer Dr. Bradford Young stated in the news release. “The ABLE method will enable scientists worldwide to benefit from the advantages of our PCT platform technology for cancer profiling and drug development, as reported by ProCan scientists and their colleagues. We believe the ABLE method has the potential to help transform the way cancer is diagnosed and treated for improved patient outcomes.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
